BiotechTube

Isatuximab

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

AL Amyloidosis

Conditions

AL Amyloidosis

Trial Timeline

Feb 11, 2022 → Mar 1, 2026

NCT ID
NCT05066607

About Isatuximab

Isatuximab is a phase 2 stage product being developed by Bristol Myers Squibb for AL Amyloidosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05066607. Target conditions include AL Amyloidosis.

What happened to similar drugs?

0 of 12 similar drugs in AL Amyloidosis were approved

Approved (0) Terminated (2) Active (10)
🔄NTLA-2001 + PlaceboRegeneron PharmaceuticalsPhase 3
🔄PatisiranAlnylam PharmaceuticalsPhase 3
🔄PatisiranAlnylam PharmaceuticalsPhase 3
🔄Nucresiran + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3
🔄Vutrisiran + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3
🔄Placebo + PatisiranAlnylam PharmaceuticalsPhase 3
🔄patisiran (ALN-TTR02) + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05066607Phase 2Recruiting

Competing Products

20 competing products in AL Amyloidosis

See all competitors
ProductCompanyStageHype Score
ZN-d5Zentalis PharmaceuticalsPhase 1/2
22
VELCADEJohnson & JohnsonPhase 1/2
32
ABBV-383 (Etentamig)AbbViePhase 1/2
39
Venetoclax + Dexamethasone + DaratumumabAbbViePhase 1/2
24
Eplontersen Solution for InjectionAstraZenecaPhase 1
29
Treatment of transthyretin (ATTR) amyloidosis in observational study settingAstraZenecaPre-clinical
33
Carfilzomib + DexamethasoneAmgenPhase 1
29
IdelalisibGilead SciencesPhase 2
27
TafamidisPfizerPre-clinical
26
TafamidisPfizerPre-clinical
30
Fx-1006APfizerPhase 2
35
tafamidisPfizerPre-clinical
26
Cyclophosphamide + Dexamethasone + Elotuzumab + LenalidomideBristol Myers SquibbPhase 2
31
Bortezomib + Cyclophosphamide + Dexamethasone + IsatuximabSanofiPhase 1
33
Bendamustine Hydrochloride + IsatuximabSanofiPhase 2
27
NC-503 (Anti-amyloidotic (AA) Agent)GSK plcPhase 2/3
38
NTLA-2001 + PlaceboRegeneron PharmaceuticalsPhase 3
44
LinvoseltamabRegeneron PharmaceuticalsPhase 1/2
39
ALN-TTR01 + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 1
26
PatisiranAlnylam PharmaceuticalsPhase 3
37